plus 3, Anti-depressant Paroxetine Linked to Breast Cancer Deaths - PR Inside |
- Anti-depressant Paroxetine Linked to Breast Cancer Deaths - PR Inside
- Breast Cancer Treatment in Large, Fewer Doses of Radiotherapy Lessens ... - PR Inside
- Research and Markets: Breast Cancer - Drug Pipeline Analysis and ... - Businesswire.com
- Low forms of cyclin E reduce breast cancer drug's effectiveness - PhysOrg
| Anti-depressant Paroxetine Linked to Breast Cancer Deaths - PR Inside Posted: 09 Feb 2010 09:00 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. 2010-02-10 06:00:19 -
February 9, 2010 /EIN PRESSWIRE/ Researchers at the University of Toronto have found that breast cancer patients taking the anti-depressant paroxetine at the same as tamoxifen, a drug for breast cancer recovery, are more likely to die from the disease. According to the Mail Online, paroxetine, sold under the brand names Paxil and Seroxat, interferes with the effects of tamoxifen.A spokesman for GlaxoSmithKline, the maker of the Paxil and Seroxat, said the company had updated warnings on the labels of the drugs in 2008. Read more about this story at Breast Cancer News Today:
Latest Tamoxifen & Breast Cancer news - breastcancer.einnews.com/news/tamoxifen-breast-cancer
About EIN Presswire
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Breast Cancer Treatment in Large, Fewer Doses of Radiotherapy Lessens ... - PR Inside Posted: 09 Feb 2010 09:15 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. 2010-02-10 06:10:14 -
The study found that women who received the larger doses experienced less skin changes than those subjected to the normal dose. These larger, less-frequent doses also reduce the total amount of radiation delivered over the course of the breast cancer treatment.Meg McArthur, from the Breakthrough Breast Cancer charity, told The Telegraph: "Radiotherapy is important in reducing the chance of cancer coming back but women have told Breakthrough that attending many sessions can be both physically and emotionally draining. Anything that has the potential to deliver radiotherapy treatment in a way that could benefit a patient's quality of life is to be welcomed." Read more about this story at Breast Cancer News Today:
Latest Radiation Therapy news - breastcancer.einnews.com/news/radiation-therapy-breast-cancer Located at breastcancer.einnews.com, Breast Cancer News Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest breast cancer news from around the world, saving them valuable time they'd spend searching for information. New users to Breast Cancer News Today can enjoy a no-obligation, one-week free trial.
About EIN Presswire
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Research and Markets: Breast Cancer - Drug Pipeline Analysis and ... - Businesswire.com Posted: 08 Feb 2010 12:55 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9064f1/breast_cancer_dr) has announced the addition of GlobalData 's new report "Breast Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
Breast Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 GlobalData, the industry analysis specialist, has released its latest research, Breast Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 which provides key data, information and analysis on the breast cancer market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with breast cancer, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the breast cancer market. The Breast Cancer Therapeutics Market is Forecast to Show High Growth Until 2016 GlobalData's analysis suggests that the global breast cancer market was worth $8.7 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 9.6% for the next seven years to reach $16.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. Increases in the treatment seeking population, the diagnosis population and the availability new first-in-class therapies with better safety and efficacy are expected to drive the growth of the breast cancer market. Breast Cancer Market has Strong Competition Between the Several Marketed Combinations and Targeted Therapies GlobalData analyzed the current competitive landscape for breast cancer drugs and found the competition to be strong. There are more than 30 marketed products for the treatment of breast cancer, which include chemotherapies, combinations and targeted therapies. Chemotherapy regimens, combination therapies and targeted therapies have adverse side-effects, sometimes fatal, despite their improved efficacy profiles. Also, evidence of resistance to HER2-targeted trastuzumab therapy in metastatic breast cancer patients and in early invasive phases of the disease has raised concerns, meaning that new targeted therapies are required. New entrants into the market will be forced to match or exceed the efficacy and safety profiles of the currently marketed products. A Lucrative Market with High Unmet Need GlobalData has found that the global breast cancer market is a highly lucrative market with high levels of unmet need. The market has several hormonal therapies, chemotherapies, combinations and targeted therapies, which target patients with different disease characteristics. The efficacy profiles of these products have improved over the years, however, the safety profiles of these drugs are still unacceptable. Although the targeted therapies significantly improve efficacy in select patient segments, they are costlier and also have severe adverse effects. Therefore, the breast cancer market has high levels of unmet need that can be fulfilled by products that target underserved patient populations and offer improved safety and efficacy profiles. Opportunity and Unmet Need in the Breast Cancer Market, 2010 Scope The scope of the report includes:
Reasons to buy The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Key Topics Covered: 1 Table of contents 2 Breast Cancer Market: Market Characterization 3 Breast Cancer Market: Competitive Assessment 4 Breast Cancer Market: Pipeline Assessment 5 Breast Cancer Market: Implications for Future Market Competition 6 Breast Cancer Market: Future Players in the Breast Cancer Market 7 Breast Cancer Market: Appendix Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/9064f1/breast_cancer_dr Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. This posting includes an audio/video/photo media file: Download Now |
| Low forms of cyclin E reduce breast cancer drug's effectiveness - PhysOrg Posted: 09 Feb 2010 10:52 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. The M. D. Anderson research, led by Khandan Keyomarsi, Ph.D., professor in M. D. Anderson's Department of Experimental Radiation Oncology and the Hubert L. and Olive Stringer Professor in Medical Oncology, found evidence that women whose cancers express the LMW-E are more likely to develop resistance to letrozole. However, their research also showed that treating breast cancer cells with a cyclin-dependent kinase 2 (CDK2) inhibitor can reverse letrozole resistance. Cyclin E is one of the proteins that regulates the cell cycle, influencing how rapidly a cell passes through the four phases and divides. In tumor cells, cyclin E is converted to low-molecular weight forms, an event that does not occur in normal cells. High levels of LMW-E accelerate the cell's transition through the G1phase, an important checkpoint that can arrest the cell cycle if DNA damage is detected. Elevated levels of LMW-E have been linked to uncontrolled cell proliferation and a poor outcome in breast cancer patients. Outwitting Drug Resistance Keyomarsi estimated that approximately 70 percent of all breast cancer patients are estrogen receptor positive (ER+), of which a large percentage are post-menopausal, and would thereby be a candidate to receive an aromatase inhibitor as maintenance therapy. Aromatase inhibitors can reduce the risk of early metastasis among postmenopausal women with ER+ breast cancer. However, not every patient responds to aromatase inhibitors, and those who do will develop resistance to the drugs over time, explained Keyomarsi. Understanding the mechanisms behind this resistance has been a long-standing goal in breast cancer research. The M. D. Anderson team hypothesized that ER+ breast cancer patients whose tumors express the LMW forms of cyclin E would be less responsive to treatment with an aromatase inhibitor. To test their hypothesis, the researchers exposed aromatase-overexpressing MCF-7/Ac1 breast cancer cells to the full-length form of cyclin E or to the LMW-E forms ("low forms").
"We found that we could negate the growth inhibitory effects of letrozole with the low forms of cyclin E but not with the wild-type cyclin E," said Keyomarsi, the study's senior author. "The mechanism behind this is that the low forms of cyclin E increase the activity of the cyclin E complex, and this complex is what mediates the negative effects." CDK2 Inhibitor Restores Letrozole's Growth Inhibition After confirming that the LMW forms of cyclin E suppress the anti-proliferative effects of letrozole, the researchers examined whether a CDK2 inhibitor could reverse the drug resistance in the unresponsive breast cancer cells. "We challenged the aromatase-overexpressing cells with either the wild-type or the low forms of cyclin E and then treated them with the CDK2 inhibitor roscovitine," Keyomarsi said. "When we did that, we could kill all the cells." The researchers also looked back at the results of another ongoing study from their group in which 128 ER+ breast cancer patients were treated with an aromatase inhibitor. "Of those, 100 expressed normal levels of wild-type cyclin E, and 28 overexpressed the low forms," Keyomarsi said. "When we looked at recurrence, three of the hundred with wild-type cyclin E had experienced a recurrence compared to four of the twenty-eight with the low forms. That in itself tells us there is a huge difference between the two groups of patients based on the pattern of expression of normal versus low forms of cyclin E." Of the seven patients who had a recurrence, six had high levels of cyclin E activity. Keyomarsi noted that these patients can be treated with a CDK2 inhibitor, which is now clinically available. "I believe that in the very near future we will be able to take advantage of the knowledge we now have about the low forms of cyclin E, and identify the patients who have these forms and devise a personalized treatment," Keyomarsi added. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment